Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VE 202

Next Previous
Drug Profile

VE 202

Alternative Names: JNJ 67670187; VE-202

Latest Information Update: 19 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vedanta Biosciences
  • Developer Janssen; Vedanta Biosciences
  • Class Anti-inflammatories; Bacteria; Immunotherapies
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators; Regulatory T-lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Inflammatory bowel diseases; Ulcerative colitis
  • No development reported Autoimmune disorders

Most Recent Events

  • 19 Oct 2025 Vedanta Biosciences terminates a phase II trial in Ulcerative colitis in USA, Australia, Bulgaria, Czech Republic, Hungary, Lithuania, the Netherlands, United Kingdom, Ukraine, Poland (PO) as following review of part 1 study data, the sponsor decided to terminate the study with immediate effect. Results indicated that VE202 was not superior to placebo on the primary or any of the secondary endpoints. No new safety concerns were observed (NCT05370885)
  • 13 Aug 2025 Efficacy and adverse events data from a phase II trial in Ulcerative colitis released by PureTech Health
  • 08 May 2024 Phase-II clinical trials in Ulcerative colitis (In adults, In the elderly) in United Kingdom, Ukraine, Poland, Czech Republic, Bulgaria, Australia (PO) (NCT05370885)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top